A Novel diagnostic method using methylation of the cysteine dioxygenase 1 gene promoter DNA-Establishment of pancreatic fuluid DNA cytology test for pancreatic ductal adenocarcinoma

A Novel diagnostic method using methylation of the cysteine dioxygenase 1 gene promoter DNA-Establishment of pancreatic fuluid DNA cytology test for pancreatic ductal adenocarcinoma - A prospective case series study on pancreatic fuluid DNA cytology test for pancreatic ductal adenocarcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036413

Enrollment

350

Registered

2019-04-04

Start date

2016-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients suspected with pancreatic ductal adenocarcinoma 2) Patients who had a high-risk factor of PDAC including chronic pancreatitis of pancreatic ductal adenocarcinoma 3) Patients who underwent ERP for a definitive diagnosis of the pancreatic ductal adenocarcinoma. 4) Patients who underwent endoscopic EUS-FNA for a definitive diagnosis of the pancreatic ductal adenocarcinoma. 5) With written informed consent before examination

Exclusion criteria

Exclusion criteria: Patients without preoperative informed consent

Design outcomes

Primary

Measure	Time frame
Concordance rate between conventional cytology and DNA cytology	—

Secondary

Measure	Time frame
Concordance rate between histological diagnosis and DNA cytology	—

Countries

Japan

Contacts

Public ContactNobuyuki Nishizawa

Kitasato University School of Medicine Department of Surgery

dm14018v@st.kitasato-u.ac.jp042-778-8111

Outcome results